Marijo Bilušić

4.0k total citations
113 papers, 2.0k citations indexed

About

Marijo Bilušić is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Marijo Bilušić has authored 113 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 37 papers in Immunology. Recurrent topics in Marijo Bilušić's work include Cancer Immunotherapy and Biomarkers (45 papers), Prostate Cancer Treatment and Research (39 papers) and Immunotherapy and Immune Responses (34 papers). Marijo Bilušić is often cited by papers focused on Cancer Immunotherapy and Biomarkers (45 papers), Prostate Cancer Treatment and Research (39 papers) and Immunotherapy and Immune Responses (34 papers). Marijo Bilušić collaborates with scholars based in United States, Croatia and New Zealand. Marijo Bilušić's co-authors include James L. Gulley, Ravi A. Madan, Jeffrey Schlom, Christopher R. Heery, Renee N. Donahue, Margaret E. Gatti‐Mays, Jennifer L. Marté, Julius Strauss, Julie Collins and Fatima Karzai and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marijo Bilušić

106 papers receiving 2.0k citations

Peers

Countries citing papers authored by Marijo Bilušić

Since Specialization

Citations

This map shows the geographic impact of Marijo Bilušić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marijo Bilušić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marijo Bilušić more than expected).

Fields of papers citing papers by Marijo Bilušić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marijo Bilušić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marijo Bilušić. The network helps show where Marijo Bilušić may publish in the future.

Co-authorship network of co-authors of Marijo Bilušić

This figure shows the co-authorship network connecting the top 25 collaborators of Marijo Bilušić. A scholar is included among the top collaborators of Marijo Bilušić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marijo Bilušić. Marijo Bilušić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE). 2024 ·Journal of Clinical Oncology ·(unknown), Nicholas I. Simon, Daniel M. Girardi, Lisa Ley, (unknown), (unknown), (unknown), Salah Boudjadi, (unknown), Elizabeth Smith, (unknown), Scot A. Niglio, Sandeep Gurram, Marijo Bilušić, Seth M. Steinberg, Andrea B. Apolo	0
2	Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer 2024 ·Cancer Research ·Ling Zhang, Clara I. Troccoli, (unknown), (unknown), Erin A. Jackson, Ping Shu, (unknown), Wensi Tao, Deukwoo Kwon, Xi Chen, (unknown), Mercè Jordà, Surinder Kumar, David B. Lombard, James L. Gulley, Marijo Bilušić, A. Craig Lockhart, Annie Beuve, Priyamvada Rai	2
3	A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors 2023 ·The Oncologist ·Margaret E. Gatti‐Mays, Nicholas Tschernia, Julius Strauss, Ravi A. Madan, Fatima Karzai, Marijo Bilušić, Jason M. Redman, Houssein Abdul Sater, Charalampos S. Floudas, (unknown), Renee N. Donahue, Caroline Jochéms, Jennifer L. Marté, (unknown), Sheri McMahon, Elizabeth Lamping, Lisa M. Cordes, Jeffrey Schlom, James L. Gulley	9
4	Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide 2023 ·European Urology Oncology ·Shruti U. Gandhy, Fatima Karzai, Marijo Bilušić, Sheri McMahon, Lisa M. Cordes, Jennifer L. Marté, Amy J. Weisman, Timothy Perk, Liza Lindenberg, Esther Mena, Barış Türkbey, Philip M. Arlen, William L. Dahut, William D. Figg, Peter L. Choyke, James L. Gulley, Ravi A. Madan	1
5	Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy? 2022 ·Journal of Clinical Investigation ·(unknown), Marijo Bilušić, Kerry L. Burnstein	5
6	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer 2022 ·The Oncologist ·Jason M. Redman, (unknown), Benjamin A. Weinberg, Renee N. Donahue, Shruti U. Gandhy, Margaret E. Gatti‐Mays, Houssein Abdul Sater, Marijo Bilušić, Lisa M. Cordes, Seth M. Steinberg, Jennifer L. Marté, Caroline Jochéms, (unknown), John L. Marshall, Sheri McMahon, (unknown), Jeffrey Schlom, James L. Gulley, Julius Strauss	30
7	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1) 2022 ·Prostate Cancer and Prostatic Diseases ·Marijo Bilušić, (unknown), Renee N. Donahue, Susan Wróblewski, Matthew R. Zibelman, Pooja Ghatalia, Eric A. Ross, Fatima Karzai, Ravi A. Madan, William L. Dahut, James L. Gulley, Jeffrey Schlom, Elizabeth R. Plimack, Daniel M. Geynisman	17
8	Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer 2022 ·International Journal of Radiation OncologyBiologyPhysics ·Benjamin Rich, (unknown), (unknown), Benjamin Spieler, Brandon A. Mahal, (unknown), Marijo Bilušić, Matthew C. Abramowitz, Alan Pollack, Alan Dal Pra	4
9	Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells 2021 ·Cancer Research Communications ·Austin T.K. Hoke, Michelle R. Padget, Kellsye P. Fabian, Anjali Nandal, Gary L. Gallia, Marijo Bilušić, Patrick Soon‐Shiong, James W. Hodge, Nyall R. London	14
10	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) 2021 ·Journal for ImmunoTherapy of Cancer ·Marijo Bilušić, Sheri McMahon, Ravi A. Madan, Fatima Karzai, (unknown), Renee N. Donahue, Claudia Palena, Caroline Jochéms, Jennifer L. Marté, Charalampos S. Floudas, Julius Strauss, Jason M. Redman, Houssein Abdul Sater, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom, James L. Gulley	43
11	957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 2021 ·Annals of Oncology ·Julius Strauss, Margaret E. Gatti‐Mays, Byoung Chul Cho, Andrew Hill, Sébastien Salas, Edward F. McClay, Jason M. Redman, Houssein Abdul Sater, Elizabeth Lamping, Jennifer L. Marté, Lisa M. Cordes, Marijo Bilušić, Fatima Karzai, Ravi A. Madan, Jeffrey Schlom, (unknown), Laureen S. Ojalvo, James L. Gulley	5
12	Neoadjuvant Immunotherapy: An Evolving Paradigm Shift? 2020 ·JNCI Journal of the National Cancer Institute ·Marijo Bilušić, James L. Gulley	8
13	<p>Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date</p> 2020 ·Cancer Management and Research ·Vincent Chau, Marijo Bilušić	27
14	Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date 2020 ·SHILAP Revista de lepidopterología ·Vincent Chau, Marijo Bilušić	2
15	681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc) 2020 ·Annals of Oncology ·Ravi A. Madan, Susan F. Slovin, Lauren C. Harshman, Xiao X. Wei, Marijo Bilušić, Fatima Karzai, Renee N. Donahue, (unknown), Julius Strauss, Lisa M. Cordes, Philip M. Arlen, Myrna Rauckhorst, Susan Wróblewski, Anna Couvillon, Amy Hankin, N. Williams, William L. Dahut, Jeffrey Schlom, Philip W. Kantoff, James L. Gulley	1
16	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors 2018 ·Clinical Cancer Research ·Julius Strauss, Christopher R. Heery, Joseph W. Kim, Caroline Jochéms, Renee N. Donahue, (unknown), Sheri McMahon, Elizabeth Lamping, Jennifer L. Marté, Ravi A. Madan, Marijo Bilušić, Matthew R. Silver, (unknown), Jeffrey Schlom, James L. Gulley	116
17	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review 2016 ·Clinical Genitourinary Cancer ·(unknown), Pooja Ghatalia, Samuel Litwin, Eric M. Horwitz, Robert G. Uzzo, Richard E. Greenberg, Rosalia Viterbo, Daniel M. Geynisman, Alexander Kutikov, Elizabeth R. Plimack, Marc C. Smaldone, Yu‐Ning Wong, Marijo Bilušić	16
18	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines 2012 ·Seminars in Oncology ·Ravi A. Madan, Marijo Bilušić, Christopher R. Heery, Jeffrey Schlom, James L. Gulley	64
19	Immunotherapy in prostate cancer: Emerging strategies against a formidable foe 2011 ·Vaccine ·Marijo Bilušić, Christopher R. Heery, Ravi A. Madan	17
20	Genetically Hypertensive Brown Norway Congenic Rat Strains Suggest Intermediate Traits Underlying Genetic Hypertension 2008 ·Croatian Medical Journal ·Marijo Bilušić, Carol Moreno, (unknown), Michael Tschannen, Eugenie L. Harris, (unknown), Caryn M. Thompson, Murray R. Grigor, Alan B. Weder, Eric Boerwinkle, Steven C. Hunt, J. David Curb, Howard J. Jacob, Anne E. Kwitek	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact